Leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1) is a transmembrane protein with an ectodomain containing 15 leucine-rich repeats (LRRs) homologous to mammalian decorin and the Drosophila kekkon1 gene. In this study, we demonstrate that a soluble ectodomain of LRIG1, containing only the LRRs, inhibits ligandindependent epidermal growth factor receptor (EGFR) activation and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. However, when a functional EGFR gene is introduced in these cells, they become growth-inhibited by soluble LRIG1 protein. Furthermore, we demonstrate the existence of high-affinity (K d ¼ 10 nM) binding sites on the A431 cells that can be competitively displaced (up to 75%) by molar excess of EGF. Even more powerful effects are obtained with a chimeric proteoglycan harboring the N-terminus of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain. Both proteins also inhibit ligand-dependent activation of the EGFR and extracellular signal-regulated protein kinase 1/2 signaling in a rapid and dose-dependent manner. These results suggest a novel mechanism of action evoked by a soluble ectodomain of LRIG1 protein that could modulate EGFR signaling and its growthpromoting activity. Attenuation of EGFR activity without physical downregulation of the receptor could represent a novel therapeutic approach toward malignancies in which EGFR plays a primary role in tumor growth and survival.
Introduction
The epidermal growth factor receptor (EGFR) plays a critical role in normal embryonic development and, as a mediator of cell proliferation, it can also drive the growth of tumors through ligand or receptor overexpression or as a receptor gain-of-function mutation (Carpenter, 2000; Carraway and Sweeney, 2001) . During evolution, a number of positive and negative regulatory mechanisms for the EGFR signaling have been developed (Moghal and Sternberg, 1999; Schlessinger, 2003) . One such mechanism is provided by members of the Kekkon family of transmembrane proteins. The founding member of this family, Kek1, was originally isolated during a screen for genes expressed in Drosophila central nervous system (Musacchio and Perrimon, 1996) and was subsequently shown to inhibit EGFR activity during oogenesis (Ghiglione et al., 1999) , as well as in the developing eye and wing (Alvarado et al., 2004a, b; Ghiglione et al., 2003) . In Drosophila, Kek1 is a transcriptional target of the EGFR where it attenuates receptor activity through an inhibitory feedback loop (Ghiglione et al., 1999) . Kek1 is one of six Kekkon family members, all of which share a similar architecture: seven leucine-rich repeats (LRR) capped by two Cys-rich flanking domains, a single Ig domain, a transmembrane domain and a cytoplasmic tail. Kek1 is the only member that inhibits EGFR activity (Alvarado et al., 2004a) as shown by the discovery of two finite classes of disrupted Kek1 alleles (Alvarado et al., 2004b) . Class I mutant alleles have mutations in the LRRs, whereas class II alleles have mutations in the flanking Cys-rich and immunoglobulin (Ig) domains. These mutant alleles are not only physically but also functionally distinct. Class I alleles reduce Kek1 affinity for the EGFR, whereas class II alleles disrupt Kek1 subcellular localization, thereby altering Kek1 ability to interact with the EGFR (Alvarado et al., 2004b) . Kek1 is highly conserved across species during evolution. In fact, orthologs of Kek1 are found in three Dipteran species, suggesting that Kek1 ability to suppress EGFR activity was present over 40-65 million years ago (Derheimer et al., 2004) . Ectopic expression of Kek1 in mammalian cells leads to an interaction with all the four members of the ErbB family of receptor tyrosine kinase, and to a suppression of growth factor binding and receptor activation (Ghiglione et al., 2003) . Kekkon members are absent in vertebrates and the invertebrate Caenorhabditis elegans. However, these species express a family of transmembrane proteins containing both LRRs and Ig domains, called LIG (Suzuki et al., 1996; Carraway and Sweeney, 2001; Nilsson et al., 2001; Suzuki et al., 2002) or LRIG (Nilsson et al., 2003; Guo et al., 2004; Holmlund et al., 2004) , considered to be distant family relatives.
The mammalian LRIG1 protein contains 15 LRRs, three Ig repeats, a transmembrane domain and a cytoplasmic tail. LRIG1 is located on chromosome 3p14 (Nilsson et al., 2001) , a region frequently deleted in various human cancers, consistent with reduced or absent expression in renal cell carcinomas and various transformed cell lines (Hedman et al., 2002; Thomasson et al., 2003) . Notably, mice deficient in Lrig1 show a psoriasis-like epidermal hyperplasia (Suzuki et al., 2002) , with a phenotype resembling that observed in transgenic mice over-expressing the two EGFR ligands tumor growth factor (TGF)-a and amphiregulin, in the stratified squamous epithelia (Cook et al., 1997; Vassar and Fuchs, 1991) . Consistent with a role in attenuating EGFR signaling, expression of the transmembrane LRIG1 promotes receptor ubiquitination and degradation (Gur et al., 2004; Laederich et al., 2004) .
We have previously shown that decorin, a secreted small leucine-rich proteoglycan (Iozzo, 1999) , is capable of directly interacting with the EGFR Santra et al., 2002) and downregulating its activity both in vitro and in vivo (Csorda´s et al., 2000; Reed et al., 2002; Reed et al., 2005) . Thus, we hypothesized that a soluble form of LRIG1 could similarly affect the EGFR signaling pathway. In this study, we demonstrate that the ectodomain of LRIG1 (LRIG1 ecto ), containing only the LRRs and flanking Cys-rich caps, inhibits both ligand-dependent and ligand-independent EGFR activation and extracellular signal-regulated protein kinase1/2 (Erk1/2) signaling in a dose-dependent manner, and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. We demonstrate the existence of highaffinity (K d ¼ 10 nM) binding sites on the A431 cells, and the vast majority of these (up to 75%) can be competitively displaced by EGF. A chimeric proteoglycan harboring the N-terminal part of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain (Dcn-LRIG1 ecto ), shows even more powerful effects. These results suggest that the soluble ectodomain of LRIG1 could act as a negative regulator of the EGFR signaling pathways.
Results

Alignment of LRRs of LRIG1, decorin and Kek1
The mammalian LRIG1 protein contains 15 LRRs, three Ig repeats, a transmembrane domain and a cytoplasmic tail. As decorin contains only LRRs and yet has a biological activity similar to that of Kek1 and LRIG1, we studied in detail the LRR regions in LRIG1, decorin and Kek1, with the premise that the LRR domain is the actual interacting domain between these molecules and the EGFR. The LRRs of these three molecules aligned quite well (Figure 1a) . Alignment of the abutting Cys-rich regions of all three molecules revealed a close homology of the three, especially in the N-terminal Cys-rich region (Figure 1b) . However, our analysis revealed a most interesting relationship among the three proteins: both decorin and Kek1 align nearly identically over a central portion of LRIG1's repeats, with the exception of LRIG1 LRR [8] [9] , where a conserved deletion in both decorin and Kek1 exists relative to LRIG1 (Figure 1c) . The deletion removes one-half of LRR 8 and one-half of LRR 9 , resulting in the relative loss of one complete LRR in decorin and Kek1 as compared to LRIG1. The primary region of decorin shown to interact with EGFR is LRR 6 (Santra et al., 2002) , which corresponds to LRR 10 of LRIG1 and to LRR 3 of Kek1, respectively. Conceivably this region could be important in a putative LRIG1-EGFR interaction. This is remarkable, because a recent study has identified that mutations in the LRR 2-3 of Kek1 cause a reduced affinity for the EGFR (Alvarado et al., 2004b) . Especially important is Gly 160 in Kek1's LRR 2 , suggesting that this residue has a crucial role in directing Kek1 interaction with the EGFR. Two of these mutant alleles encode a change to Ser (G160S), whereas a third mutant allele of Kek1 encodes a conversion to Asp (G160D); all these mutants result in complete suppression of Kek1 activity (Alvarado et al., 2004b) . On the basis of these results, we predict that a similar region in LRIG1 would be involved in EGFR binding, in analogy to decorin and Kek1.
Expression and characterization of human recombinant LRIG1
ecto and Dcn-LRIG1 ecto To investigate the role of soluble LRIG1, we generated two truncated variants of LRIG1: one containing the 15 LRRs and a chimera containing the LRRs fused to the first 24 amino-acid residues of human decorin ( Figure 1d ). The latter contains the Ser-Gly sequence responsible for substitution with a single glycosaminoglycan chondroitin/dermatan side chain (Iozzo, 1998) . The recombinant LRIG1 ecto generated in 293-EBNA cells migrated as a single band of B65 kDa, consistent with a glycosylated protein (the predicted size from the sequence is B51 kDa). In contrast, Dcn-LRIG1 ecto migrated primarily as a broadband centering at B120 kDa, typical of proteoglycan migration in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), in addition to unglycanated protein core migrating at B65 kDa as the parent LRIG1 ecto (Figure 1e ). Condroitinase ABC digestion, which cleaves both chondroitin and dermatan sulfate, converted the Dcn-LRIG1 ecto into the protein core (Figure 1f ), indicating that Dcn-LRIG1
ecto was substituted with a chondroitin/dermatan sulfate chain as decorin.
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Next, we determined the appearance of the soluble LRIG1 ectodomain by rotary shadowing electron microscopy. Nearly all the images of isolated LRIG1 ecto and Dcn-LRIG1
ecto showed an arch-shaped structure (Figure 2a) , slightly larger and more extended than that observed with the decorin protein core (Keene et al., 2000) . Quantitative analysis of 300 LRIG1 ecto molecules (Figure 2b ) gave an average size of 14.871.4 nm (the distance between the two arms) by 10.571.4 nm (the distance between the base of the arch and the apex).
Analysis of 150 Dcn-LRIG1
ecto molecules showed them to be of similar but not identical size to LRIG1 ecto , with dimensions of 15.871.9 by 1171.6 nm.
LRIG1
ecto and Dcn-LRIG1 ecto selectively inhibit the growth of EGFR-expressing cells To determine whether soluble recombinant LRIG1 ecto and Dcn-LRIG1
ecto would influence cell growth in a paracrine manner and to mimic a more physiological situation, we established a co-culture system where 293-EBNA cells, either wild-type or stably expressing cells, were seeded in the top wells of trans-well dishes, whereas A431 cells were seeded in the bottom wells. Under such conditions, only soluble factors released from the cells would be able to diffuse through the 0.2-mm membrane separating the two compartments. Notably, both LRIG1 ecto and Dcn-LRIG1 ecto markedly inhibited the growth of A431 squamous carcinoma cells in the presence of full serum (Figure 3a) . At 6 days of coculture, the growth of A431 cells was inhibited by B55 and B68% when co-cultured with LRIG1
ecto -or Dcn-LRIG1
ecto -secreting cells, respectively (Po0.01). To eliminate the possibility that the growth-inhibitory activity was caused by an unknown activity present in the clonal cells, we transfected 293-EBNA cells with the empty pCEP-Pu vector and compared the effects to those obtained by LRIG1-secreting cells using Both algorithms were implemented in Biology Workbench (workbench.sdsc.edu). Identical residues are green, and conserved residues are blue. (b) Alignments of the cysteine-rich regions that cap the LRRs of LRIG1, decorin and Kek1. The residue color scheme is identical to (a), with the exception of conserved cysteine residues, which are colored yellow. The locations of cysteine residues at the N-terminal region in both decorin and LRIG1 match the canonical CX 3 CXCX 6 C pattern of class I SLRPs (Iozzo and Murdoch, 1996; Iozzo, 1997) . The Cys-rich region of Kek1 contains a gap of 10 residues before the final cysteine, more reminiscent of class II SLRPs that by definition have a gap of nine residues. The C-terminal Cys-rich region of LRIG1 and Kek1 contains a conserved LRR protein C-terminal region (CXCX 21 CX 20-21 C) as identified by the NCBI Conserved Domain Database (www.ncbi.nlm.nih.gov). The C terminus of decorin, while also Cys-rich, contains a different pattern of residues. ecto (B200 ng) before and after chondroitinase ABC (Chase) digestion using an anti-His antibody. Note that the chimeric proteoglycan is converted to the protein core following removal of the chondroitin/dermatan sulfate side chain.
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S Goldoni et al co-culture experiments as described above. The results showed that after 4 days of co-culture, there was B45% inhibition of growth caused by the LRIG1 ectodomainsecreting cells (Po0.05, Figure 3b ). To establish more directly that the growth inhibitory effects were owing to the presence of the recombinant proteins, rather than to the physical presence of the 293-EBNA cells, we performed growth assays using either conditioned medium (5 Â concentrated by ultrafiltration) or purified recombinant proteins. The concentrated conditioned media containing either recombinant protein markedly (>70%) suppressed the growth of HeLa and A431 (Figure 3c ). Similar results were obtained with recombinant LRIG1 ecto (0.45 mM) ( Figure 3d ). Notably, both A431 cells, which contain B2.5 Â 10 6 EGFR per cell (Csorda´s et al., 2000) , and HeLa cells, which contain B5 Â 10 4 receptors per cell (Berkers et al., 1991; Sigismund et al., 2005) , equally responded to the growth inhibitory activity evoked by LRIG1 ecto and Dcn-LRIG1 ecto . As in the case of the coculture, the media from empty vector-transfected cells had no significant effect on the growth of either A431 or HeLa cells (Figure 3c ). Moreover, we performed a growth inhibition assay using an A431 clone recently produced in our laboratory by long-term treatment with EGF (Zhu et al., 2005) . Although these cells express B40% of the EGFR levels expressed by wild-type cells, they were similarly growth inhibited by both the ectodomain of LRIG1 and Dcn-LRIG1 (not shown).
These findings suggest that the biological activity of these two proteins does not depend on receptor density.
The growth-suppressive activity of both LRIG1 ecto and Dcn-LRIG1 ecto was further assessed in MDA-468 breast carcinoma cells, which have an amplified EGFR and express B1.9 Â 10 6 receptors per cell (Filmus et al., 1985 (Filmus et al., , 1987 Ennis et al., 1989) . In these experiments, the recombinant proteins (0.45 mM) were added every day together with fresh medium containing 10% fetal calf serum. Notably, there was a B50% inhibition by LRIG1 ecto and >90% inhibition by Dcn-LRIG1 ecto ( Figure 3e ). These findings suggest that the soluble LRRs of LRIG1 and especially the chimeric proteoglycan can affect the growth of a variety of transformed cell lines that express EGFR.
EGFR expression is required for the activity of LRIG1 ectodomain To further investigate whether EGFR expression was required for LRIG1-mediated cytostatic effects, we utilized CHO-K1 cells, which do not express EGFR ( Figure 4a ). We found that CHO-K1 cells, in contrast to A431 cells, did not respond to the medium containing either LRIG1 ecto or Dcn-LRIG1 ecto ( Figure 4b ). Similar results were obtained when cells were exposed to recombinant LRIG1 ectodomain (not shown). Next, we tested whether CHO-K1 cells with de novo expression of EGFR would respond to LRIG1
ecto . To this end, we In these experiments, recombinant proteins (0.45 mM) were freshly added every day together with serum-containing media. Cell number was estimated by determining OD at 490 nm using the CellTiter 96 assay (Promega). The values represent the mean7s.e.m. of three measurements.
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transfected wild-type CHO-K1 cells with a vector containing the whole EGFR linked to the cyan fluorescent protein (CFP) at its C-terminus. It has been previously shown that this EGFR, carrying either a GFP or a CFP, is fully viable and signals in response to EGF, and has been successfully used to study EGFR endocytosis, trafficking and interaction with various adaptor proteins (Carter and Sorkin, 1998; Sorkin et al., 2000; Jiang and Sorkin, 2002; Jiang et al., 2003) and chemotactic responses (Bailly et al., 2000) . Immunoblotting of total cell lysates showed the expression of a B200-kDa EGFR-CFP chimera in the CHO-K1 11A3 cells ( Figure 4c ). As positive control, we used A431 cell extracts, which showed the B175 kDa EGFR. From the immunoblotting, we estimated that the CHO-K1 11A3 cells contained about 15% of the total EGFR expressed by A431 or B3.4 Â 10 5 EGFR/cell. Immunoblotting with PY20 demonstrated rapid Tyr phosphorylation of the EGFR-CFP and a number of cellular proteins upon stimulation with EGF (Figure 4d ), in agreement with published reports (Carter and Sorkin, 1998; Sorkin et al., 2000) . Fluorescence microscopy of CHO-K1 11A3 cells showed a strong endogenous EGFR-CFP signal at the cell surface (Figure 4e ), which colocalized with (Figure 4f ). When the CHO-K1 11A3 cells were exposed to recombinant LRIG1 ecto or Dcn-LRIG1 ecto (0.45 mM), there was a significant growth inhibition (Figure 4g ). These results are even more striking if we take into consideration that the cells used for these assays are a mixed population derived from mass culture, thereby eliminating the problem with 'clonality'. As in the case of the A431 and HeLa cells, media conditioned by 293-EBNA transfected with an empty pCEP-Pu vector had no appreciable effect on the growth of CHO-K1 or CHO-K1 11A3 cells (not shown). To further prove specificity (i.e., determine if EGFRtransfected cells became dependent on EGFR signaling for their growth), we utilized two different EGFRspecific tyrosine kinase inhibitors, gefitinib (Iressa) (Sordella et al., 2004; Pao and Miller, 2005) and the tyrphostin AG1478 (Levitzki and Gazit, 1995) . In contrast to the wild-type CHO-K1 cells, the EGFRexpressing CHO-K1 cells were inhibited by both kinase inhibitors in a concentration-dependent manner ( Figure  4h and i) .
Collectively, these results provide strong genetic evidence for the EGFR requirement in LRIG1-evoked activity and further validate the results presented in the previous sections.
Soluble LRIG1 ectodomain specifically interacts with the EGFR Having established the EGFR requirement for LRI-G1
ecto -mediated activity, we next determined whether a direct and specific interaction between the receptor and the soluble ligand did indeed occur with live cells. To this end, we radioiodinated recombinant LRIG1 ecto with 125 I and Iodogen beads (Pierce, Rockford, IL, USA) to reach high specific activity (1-8 Â 10 18 c.p.m./mol) and purified it via a Sephadex G-50 column. The eluted fractions (fraction nos. 12-15, Figure 5a ) gave a single peak, which was shown by SDS-PAGE and autoradiography to be pure LRIG1 ecto (Figure 5b ). Radioligand binding studies using confluent A431 cells at 41C showed saturable binding ( Figure 5c ) with a K d of 1071.2 nM (Figure 5d ). Specificity of the binding was further proven by competitive displacement of radiolabeled LRIG1
ecto by 10-and 20-fold molar excess of cold EGF (Figure 5e ; Po0.01).
Next, we performed overlay assays using increasing amounts of either BSA or LRIG1 ecto immobilized on nitrocellulose filter and then incubated with serum-free medium conditioned by A431 cells. The latter contains a soluble form of EGFR, which lacks the transmembrane and intracytoplasmic domain (Weber et al., 1984; Yarden et al., 1985) . This soluble protein (Figure 5f , top left) is derived from a 2.8 kb mRNA transcribed from a rearranged EGFR gene on chromosome 7 (Carpenter, 1987) . The results showed that the soluble EGFR specifically and dose dependently bound to immobilized LRIG1 ecto , in contrast to BSA that was unreactive. This is important because the slot-blot overlay assay utilizes non-denaturing conditions and, thus, it supports a physiological interaction. Also, the 125 I-labeled LRIG1 specifically bound to immobilized soluble EGFR but not to EGF, using similar overlay assays (not shown). This eliminates the possibility that LRIG1 might interfere with EGFR activity by blocking EGF. These findings provide for the first time a direct and specific interaction between the ectodomain of LRIG1 and the ectodomain of the EGFR where the ligand-binding region is present.
LRIG1
ecto and Dcn-LRIG1 ecto attenuate ligandindependent and ligand-dependent EGFR signaling Given the profound growth inhibitory activity of soluble LRIG1, we tested whether this biological property could be owing to interference with basal (ligand-independent) EGFR activity. Serum-starved, quiescent A431 cells ecto , as indicated. Slot blots were incubated for 16 h with serum-free media conditioned by A431 cells that contain the soluble form of EGFR, as shown in the left panel. The blots were washed extensively and incubated with an anti-EGFR antibody followed by chemiluminescence detection.
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were incubated for B2 h with increasing concentrations of either protein and the levels of total phospho-tyrosine (P-Tyr), EGFR P-Tyr1068, an established autophosphorylation site of the EGFR intracellular domain, and total EGFR were determined by immunoblotting. The results showed a marked and dose-dependent suppression of EGFR autophosphorylation for both LRIG1 ecto -and Dcn-LRIG1
ecto -treated cells (Figure 6a and c) , with an IC 50 of B2 nM for both proteins (not shown). Timecourse experiments using equimolar amounts of either protein showed a time-dependent suppression of basal EGFR activation, with T 1/2 of B45 and B10 min for LRIG1 ecto and Dcn-LRIG1 ecto , respectively (Figure 6b  and d ).
Next, we tested whether LRIG1 ecto would affect ligand-dependent activation of the EGFR. Pre-incubation of quiescent A431 cells with LRIG1
ecto for 1 or 2 h blocked EGF-induced EGFR phosphorylation at Tyr1068 by B50% (Figure 7a and b) , without affecting the endogenous EGFR levels. Similarly, phosphorylation of Erk1/2, an established downstream component of the EGFR signaling pathway, was inhibited by B35% after 1 h, and by B75% after 2 h (Figure 7c and d) .
Comparable results were obtained with Dcn-LRIG1 ecto (not shown). Using shorter incubation times (5-30 min), soluble LRIG1 ectodomain did not cause any appreciable activation of the Erk1/2 pathway (not shown).
Next, we carried out a more detailed analysis of LRIG1-dependent attenuation of EGFR signaling by performing a dose-response study. In these experiments, quiescent A431 cells were pre-incubated for 2 h with a constant dose of LRIG1 ecto or Dcn-LRIG1 ecto (0.45 mM) and in the last 10 min of incubation various concentrations of EGF were added. The results showed a marked inhibition of EGF-induced phosphorylation at Tyr1068 (Figure 7e ). Quantification of various experiments showed that at a sub-optimal EGF concentration (10 ng ml À1 ¼ 1.6 nM) EGFR activation was blocked by over 90%, while at maximal EGF concentration (16 nM) EGFR activation was blocked by B65% (Figure 7f ). Thus, soluble forms of LRIG1 containing the LRRs are capable of affecting both ligand-dependent and ligand-independent activation of the EGFR, without any appreciable downregulation of the total receptor. ecto or Dcn-LRIG1 ecto at the designated concentrations using antibodies against P-Tyr, EGFR phosphorylated at Tyr1068, a common autophosphorylation site, total EGFR and b-actin. (b, d) Time-course inhibition of EGFR phosphorylation (activation) by LRIG1 ecto (') and Dcn-LRIG1 ecto (m), respectively. The values were obtained from additional blots (not shown) and represent mean7s.e.m. of three experiments. In these experiments, quiescent A431 cells were exposed to 0.45 mM of each protein and the EGFR activation was measured by immunoblotting as in panel a, followed by scanning densitometry with the NIH Scion Image software.
LRIG1 induces neither EGFR internalization nor EGFR phosphorylation at Tyr1045
The data presented so far indicate that soluble forms of LRIG1 ectodomain do not induce a downregulation of the EGFR, as its levels were not significantly affected by these proteins. If this were the case, then, the EGFR should not be diverted into an intracellular degradation pool by soluble LRIG1 protein. To test this hypothesis, we incubated quiescent A431 cells with either recombinant protein for 30 min with or without chase for 90 min in serum-free media. Under quiescent conditions, the EGFR was localized primarily at the cell surface (Figure 8a) . Exposure of the cells to EGF evoked a rapid mobilization of the receptor into cytoplasmic vesicles (Figure 8b ), in agreement with previous studies (Carter and Sorkin, 1998; Bailly et al., 2000; Carpenter, 2000) . In contrast, exposure of the cells to either recombinant protein did not cause any appreciable EGFR movement into the cytoplasm (Figure 8c-f) . Immunofluorescence microscopy of cells exposed to LRIG1 ecto (0.45 mM) for 30 min showed a marked colocalization of both proteins at the cell surface ( Figure  8g-i) , without any significant internalization of the receptor. In agreement with these findings, recombinant LRIG1 proteins did not cause any substantial phosphorylation of EGFR at Tyr1045, whereas EGF caused up to a 30-fold increase in phosphorylation of this key amino-acid residue (Figure 8j and k) . This is important as phosphorylation at Tyr1045 creates a major docking site for c-Cbl, which mediates ligand-induced ubiquitination and downregulation of the receptor (Levkowitz et al., 1999; Grovdal et al., 2004) . In cells expressing EGFR mutated at Tyr1045, c-Cbl retains residual activity by docking to Grb2, thereby leading to the retardation of receptor endocytosis and acceleration of its recycling to the cell surface (Waterman et al., 2002) . One of the docking sites for Grb2 on the tyrosine kinase domain of the EGFR is Tyr1068 (Batzer et al., 1994; Okutani et al., 1994) . The fact that soluble LRIG1 protein negatively regulates Tyr1068 phosphorylation (see Figures 6 and 7) is in support of LRIG1-mediated inhibition of mitogenic signaling and recycling of the receptor to the cell surface.
Collectively, our results indicate that soluble forms of LRIG1 protein attenuate EGFR activity without any significant internalization or degradation of the receptor, and provide a novel mechanism of action for this class of molecules. ecto or Dcn-LRIG1 ecto (0.45 mM); in the last 10 min of the incubation, various concentrations of EGF were added as indicated. Note the marked inhibition of EGF-induced phosphorylation at Tyr1068. (f) Quantification of three independent experiments similar to those shown in panel e. The values are the mean7s.e.m. Note that at a sub-optimal EGF concentration (1.6 nM) of EGFR activation was blocked by over 90%, whereas at maximal EGF concentration (16 nM) of EGFR activation was blocked by B65%.
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Discussion
To prevent the dire consequences of uncontrolled receptor tyrosine kinase activation, a number of controlling mechanisms, both extracellular and intracellular, have been devised during evolution. We report an additional controlling mechanism that leads to the attenuation of receptor signaling without apparent downregulation of the receptor itself. Specifically, we show that the ectodomain of LRIG1, containing only the 15 LRRs, inhibits ligand-dependent and ligandindependent EGFR activation and causes growth inhibition. Even more powerful effects were observed with a chimeric proteoglycan containing the N-terminal portion of decorin -harboring the attachment site for a single chondroitin-dermatan sulfate chain -and the ectodomain of LRIG1. LRIG1 ecto was capable of inhibiting growth factor binding, EGFR autophosphorylation and activation of the MAPK signaling cascade in response to EGF. This was confirmed by growth assays, which showed that only cells expressing EGFR were susceptible to the cytostatic effects of soluble LRIG1 ectodomain. In addition, the cytostatic effects appear to be independent of EGFR number, as both A431 and MDA-468 carcinoma cells (which have amplified EGFR) were growth inhibited as equally well as HeLa cells, which express a physiologic number of receptors. Moreover, we provide strong genetic evidence for the requirement of EGFR in LRIG1 biological activity. We employed CHO-K1 cells, which do not constitutively express detectable levels of the EGFR, and found that they did not respond to soluble LRIG1 proteins. However, when cells were genetically engineered to express a functional EGFR-CFP protein, they became responsive to soluble LRIG1 proteins and were growth inhibited by recombinant LRIG1. This is in agreement with the fact that the EGFR-CFP-expressing cells were similarly growth inhibited by EGFR-specific LRIG1 ectodomain attenuates EGFR activity S Goldoni et al tyrosine kinase inhibitors, gefitinib (Iressa) (Sordella et al., 2004; Pao and Miller, 2005) and the tyrphostin AG1478 (Levitzki and Gazit, 1995) . Furthermore, we demonstrate the existence of high-affinity (K d ¼ 10 nM) binding sites on the A431 cells; the vast majority of these (up to 75%) can be competitively displaced by EGF.
Recent evidence indicates that both Kekkon and LRIG proteins have evolved as negative regulators of receptor tyrosine kinase (Carraway and Sweeney, 2001; Gur et al., 2004; Laederich et al., 2004) . However, their modulating activity appears to be distinct: in the case of Kek1, the inhibition of receptor activation is predominant, while in the case of LRIG1, acceleration of receptor ubiquitination and degradation is the principal mechanism of action (Gur et al., 2004; Laederich et al., 2004; Rubin et al., 2005) . These data on LRIG1, however, were primarily generated with cells engineered to overexpress LRIG1, and thus, we cannot conclude that such a mechanism of action may be operational in vivo, especially when LRIG1 is widely expressed in a variety of normal tissues, but markedly suppressed in several human malignancies (Hedman et al., 2002; Thomasson et al., 2003) .
Shedding of the ectodomain may be an additional mechanism of EGFR control: generation of a soluble ectodomain of LRIG1 via limited proteolysis could attenuate EGFR signaling in a paracrine or autocrine manner. Indeed, a search of two databases for proteases (MEROPS and CUTTER) has revealed numerous potential cleavage sites (including sites cleavable by bone morphogenetic protein-1, proprotein convertase 1 and the peptidase PHEX) within the juxta-membrane region of LRIG1. This processing could liberate the extracellular domain of LRIG1 from the cell surface of malignant cells as well as stromal elements.
In contrast to the transmembranous LRIG1, we did not observe any physical downregulation of the EGFR using the soluble ectodomain. A possible explanation of our findings is that soluble forms of LRIG1 could act at the cell surface by maintaining the EGFR in a monomeric, 'attenuated' or autoinhibited state. The soluble LRIG1 protein could act in a way similar to cetuximab, a monoclonal antibody that prevents the unfolding of the EGFR, thereby keeping the receptor in an inactive, tethered configuration, which also prevents the intermolecular interactions that lead to dimerization and activation (Li et al., 2005) . This interaction not only would attenuate autocrine stimulation of the EGFR mediated by endogenously produced factors such as TGF-a, but would also reduce the stimulation evoked by EGF. This provides a novel mechanistic explanation for the marked growth inhibition in cells expressing EGFR. Utilization of a soluble form of LRIG1 and related gene products could lead to effective treatments of human malignancies in which EGFR plays a primary role. In agreement with this concept, preliminary studies in our laboratory using an orthotopic A431 tumor xenograft model have shown that soluble forms of LRIG1 protein retard in vivo tumor growth when systemically administered.
Materials and methods
Cell cultures and reagents A431, HeLa, MDA-468 and CHO-K1 cells were obtained from American tissue culture collection (Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, 100 Â antibiotic-antimycotic solution and Dulbecco's phosphate-buffered saline (DPBS) were purchased from Mediatech (Herndon, VA, USA). All the chemicals, unless specified, were purchased from Sigma (St Louis, MO, USA). Nitrocellulose membrane was purchased from Bio-Rad (Hercules, CA, USA). Recombinant human EGF and antiErk1/2 were purchased from Promega (Madison, WI, USA). Antibodies include polyclonal rabbit antibodies against the Nterminal region of decorin (Fisher et al., 1995) , the C-terminal region of the EGFR (sc-03; Santa Cruz Biotechnology, Santa Cruz, CA, USA), P-Erk1/2 and Tyr1068 and Tyr1045 (Cell Signaling Technology, Beverly, MA, USA), and monoclonal antibodies against b-actin (Sigma, St Louis, MO, USA), phospho-tyrosine (PY20; BD Transduction Laboratories, San Diego, CA, USA), EGFR (Ab-12; NeoMarkers Inc., Union City, CA, USA) and His 6 (CalBiochem, San Diego, CA, USA). Super Signal West Pico chemiluminescent substrate was purchased from Pierce.
Expression and purification of recombinant proteins and rotary shadowing electron microscopy We cloned the ectodomain of LRIG1 encompassing the 15 LRRs (Ala42 to Leu493), according to the published sequence (National center for biotechnology information (NCBI) ID no. ; AAU44786), into the pCEP-Pu vector containing the BM-40 signal peptide sequence (Kohfeldt et al., 1997) . The cloned sequence contained 452 amino acids and the expressed protein had a predicted molecular weight of B53 kDa. To generate Dcn-LRIG1 ecto , the first 24 amino acids of the decorin sequence (Met1 to Gly24), containing the glycanation site (Ser7), were cloned between the BM-40 signal peptide and LRIG1 ecto sequences. Both constructs contained a His 6 tag at their C-termini. Following complete sequencing, the vectors were stably transfected into human embryonic kidney 293-EBNA cells. Transfectants were selected in media containing G418 (250 mg ml
À1
) and puromycin (500 ng ml À1 ) for at least 4 weeks. Isolation and purification of recombinant proteins were as described previously (Mongiat et al., 2003; Gonzalez et al., 2005) . Protein purity was verified by SDS-PAGE and immunoblotting using an anti-His tag antibodies (Goldoni et al., 2004) . For rotary shadowing, samples were dissolved in 0.1 M ammonium bicarbonate buffer at various dilutions and processed as described before (Keene et al., 2000) . Images were inspected using Photoshop 7.0 and molecules were measured using the public domain NIH Image program.
Generation of cells expressing EGFR-CFP chimera and growth assays
To determine the specificity of both LRIG1
ecto and Dcn-LRIG1 ecto recombinant proteins, we transfected CHO-K1 cells, which do not express endogenous EGFR, with a chimeric EGFR-CFP vector (Sorkin et al., 2000) . Following selection in media containing G418 as above, positive clones were identified by fluorescence microscopy using appropriate filters and by Western immunoblotting with anti-EGFR antibody. Positive clones and wild-type CHO-K1 cells were tested in growth assays in the presence or absence of recombinant proteins as detailed below.
We established a co-culture system where 293-EBNA cells, either wild-type or stably expressing cells, were seeded in the LRIG1 ectodomain attenuates EGFR activity S Goldoni et al top trans-well dishes, whereas A431 cells were seeded in the bottom wells. Under such conditions, only soluble factors released from the cells would be able to diffuse through the 0.2-mm membrane separating the two compartments. Cells were grown for 5-6 days without changing the medium and curves were generated by counting the cells. In some cases, we tested media conditioned for 5 days by either wild-type 293 cells or cells secreting either recombinant protein.
In these experiments, the media were concentrated fivefold using Centriprep (Millipore Corporation, Bedford, MA, USA). In order to replenish nutrient supplies for target cells, the media were mixed 1:1 (v/v) with 2 Â DMEM and 20% serum. Doseresponse curves with recombinant LRIG1 ecto and Dcn-LRI-G1
ecto were also performed. Cell number was estimated by either direct counting or by determining OD at 490 nm using the CellTiter 96 (Promega, Madison, WI, USA) assay.
Fluorescence microscopy
Following treatment with either recombinant protein or EGF, cells were fixed with ice-cold 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 for 2 min and subjected to immunofluorescence microscopy using appropriate filters. To detect EGFR, we used either a mouse or rabbit antibody (Ab-12, NeoMarkers and sc-03, Santa Cruz, respectively), followed by fluorescein-isothiocynate (FITC)-conjugated secondary antibody (Santa Cruz). To detect LRIG1 ecto , we used a mouse anti-His antibody (Calbiochem), followed by Rhodamineconjugated secondary antibody. Cells were mounted with Vectashield medium (Vector Laboratories, Burlingame, CA, USA).
Radioligand binding assays
Approximately 20 mg recombinant LRIG1 ecto were radiolabeled using 125 I and Iodogen beads (Pierce) as described before (Mongiat et al., 2003) to reach high-specific activity (1-8 Â 10 18 c.p.m./mol) and purified via a Sephadex G-50 column. The exclude fractions were analysed by SDS-PAGE and autoradiography, pooled and used in radioligand binding studies using confluent, serum-starved A431 cells at 41C. Cells were incubated with various concentrations of 125 I-labeled LRIG1
ecto for 2 h under gentle shaking, washed several times, extracted in radioimmuno-precipitation assay (RIPA) buffer and counted in total. Competition experiments were carried out with 10 and 20 M excess EGF. Overlay assays were carried out essentially as described before (Mongiat et al., 2001) . Briefly, scalar dilutions of recombinant LRIG1 ecto or BSA were slot-blotted into nitrocellulose filters. The filters were air-dried, blocked for 18 h with 5% BSA and incubated for several hours with serum-free media conditioned for 24-48 h by A431 cells. The blots were then washed again and reacted with an anti-EGFR antibody followed by chemiluminenscence detection.
Western blots quantification and statistical analysis Immunoblots were quantified by scanning densitometry (relative densities) with Scion Image alpha 4.0.3.2 (www. scioncorp.com). For this purpose, blots low in background and showing bands below saturation levels were chosen. Background manipulations were avoided in order not to alter density values. Images were calibrated within the Scion Image program by selecting the lightest (background) and darkest area of the blot. Only curves close to linear were considered to approximate area of pixels. Differences between means were evaluated with an unpaired two-sided Student's t-test using the Sigma Plot 9 statistical package. Po0.05 was considered as significant.
Abbreviations
EGFR, epidermal growth factor receptor; LRIG1, leucine-rich repeats and immunoglobulin-like domains-1; LRIG1 ecto , a soluble form of LRIG1 containing only the extracellular leucine-rich domain; Dcn-LRIG1 ecto , a chimeric proteoglycan harboring the N-terminus of decorin fused to LRIG1 ecto ; CFP, cyan fluorescent protein; SDS-PAGE, sodium dodecylsulfatepolyacrylamide gel electrophoresis.
